Eli Lilly and Company

Eli Lilly Company

Kurt Rasmussen

John M Schaus

Vincent Patrick Rocco

Joseph H Krushinski, Jr

Dennis C Thompson

James E Audia

David T Wong

David J Hibschman

Jeffrey S Nissen

Thomas Edward Mabry

Mary Jeanne Kallman

J Jeffry Howbert

Mitchell I Steinberg

Gary Dennis Tollefson

David R Helton

Beverley Greenwood

Thomas F Bumol

Charles M Beasley, Jr

August Masaru Watanabe

Steven J Mitan

A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1,receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

Compounds having effects on serotonin-related systems

Method for treating substance abuse

This invention provides a method for treating a condition resulting from the cessation or withdrawal of tobacco or nicotine, opioids, ethanol or combinations thereof comprising administering an effective amount of 4-chloro-5-(imidazoline-2-y(amino)-6-methoxy-2-methylpyrimidine.

Method for treating substance abuse withdrawal

A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

The invention provides a method for treating a condition resulting from the cessation and withdrawal of nicotine comprising administering an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno�2,3-b!�1,5!-benzodiazepine.

Method for treating nicotine withdrawal

Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.

Pyrazolidinone CCK and gastrin antagonists and pharmaceutical

Growing community of inventors

Fishers, IN, United States of America

Kurt Rasmussen